Novo Nordisk is in the lead, but not alone. Obesity doctors say they are gearing up for demand, predicted to be high. Some ...

Study finds the GLP-1 drug liraglutide reduced migraine days by almost 50% in patients with obesity, with quality of life ...

CVS Caremark will stop covering Eli Lilly’s Zepbound. Wegovy, the GLP-1 medication to treat obesity from Lilly competitor ...

CVS is set to drop Zepbound as a medicine, but will continue to carry other popular weight loss drugs instead.

The country’s Medicines and Healthcare products Regulatory Agency’s Yellow Card scheme, the UK’s official system for ...

A study in Diabetes, Obesity and Metabolism has identified certain characteristics that might influence people's weight loss ...

According to the CDC, 1 in 5 American adults is living with obesity. In recent years, many have turned to weight loss drugs ...

GLP-1 drugs bought online or at compound pharmacies could cause harm, according to Tennessee Attorney General Jonathan ...

A new oral drug may be able to treat type 2 diabetes and obesity without impacting muscle mass as an alternative to GLP-1 ...

The first study to put two GLP-1 weight loss drugs head-to-head found Zepbound helped people lose more weight than Wegovy.

Migraines are one of the world's most common neurological conditions, impacting nearly 15% of people globally. Despite this ...

Starting July 1, CVS Caremark will stop covering Eli Lilly’s Zepbound. Wegovy, the GLP-1 medication to treat obesity from Lilly competitor Novo Nordisk, will still be covered under plans managed ...